Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB 30/05)

European Urology

Volumn 55, Issue 6, 2009, Pages 1293-1299

  Lehmann, Jan ^a,p   Suttmann, Henrik ^p,q   Albers, Peter ^b,c,k   Volkmer, Björn ^d   Gschwend, Jürgen E ^d,n   Fechner, Guido ^b   Spahn, Martin ^e   Heidenreich, Axel ^f   Odenthal, Axel ^g   Seif, Christoph ^h   Nürnberg, Nils ^a,h   Wülfing, Christian ⁱ   Greb, Christoph ^j   Kälble, Tilmann ^j   Grimm, Marc Oliver ^k   Fieseler, Claus Friedrich ^l   Krege, Susanne ^m   Retz, Margitta ⁿ   Schulte Baukloh, Heiner ^o   Gerber, Martin ^p   Hack, Markus ^p   Kamradt, Jörn ^p   Stöckle, Michael ^h,p   more..

^a Stadtisches Krankenhaus Kiel   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c KLINIKUM KASSEL   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g SLK Kliniken Heilbronn   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j KLINIKUM FULDA   (Germany)

^k UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^l Krankenhaus St Franziskus   (Germany)

^m Krankenhaus Maria Hilf   (Germany)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o MARTIN LUTHER KRANKENHAUS   (Germany)

^p SAARLAND UNIVERSITY   (Germany)

^q Urologikum Hamburg   (Germany)

more..

Author keywords

Metastatic urothelial cancer; Multimodality approach; Resection of metastases; Surgery for metastatic disease; Urothelial carcinoma metastases

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADRENAL METASTASIS; ADULT; ARTICLE; BLADDER CARCINOMA; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; DISTANT METASTASIS; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASECTOMY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROPERITONEAL CANCER; RETROSPECTIVE STUDY; SKIN METASTASIS; SMALL INTESTINE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT CARCINOMA; VISCERAL METASTASIS;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 65049090049     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.11.039     Document Type: Article

References (20)

1. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19 (2001) 666-675
2. Sternberg C.N., Yagoda A., Scher H.I., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139 (1988) 461-469
3. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
4. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
5. Loehrer Sr. P.J., Elson P., Dreicer R., et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 12 (1994) 483-488
6. Siefker-Radtke A.O., Millikan R.E., Tu S.M., et al. Phase III trial of fluorouracil, interferon α-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20 (2002) 1361-1367
7. Von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
8. Shah J.B., and McKiernan J.M. Novel therapeutics in the treatment of bladder cancer. Curr Opin Urol 14 (2004) 287-293
9. Cowles R.S., Johnson D.E., and McMurtrey M.J. Long-term results following thoracotomy for metastatic bladder cancer. Urology 20 (1982) 390-392
10. Dodd P.M., McCaffrey J.A., Herr H., et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 17 (1999) 2546-2552
11. Miller R.S., Freiha F.S., Reese J.H., Ozen H., and Torti F.M. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 150 (1993) 65-69
12. Herr H.W., Donat S.M., and Bajorin D.F. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 165 (2001) 811-814
13. Abe T., Shinohara N., Harabayashi T., et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 52 (2007) 1106-1113
14. Sweeney P., Millikan R., Donat M., et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?. J Urol 169 (2003) 2113-2117
15. Siefker-Radtke A.O., Walsh G.L., Pisters L.L., et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol 171 (2004) 145-148
16. Dimopoulos M.A., Finn L., and Logothetis C.J. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 151 (1994) 598-600
17. Oosterlinck W., Lobel B., Jakse G., Malmström P.-U., Stöckle M., and Sternberg C. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
18. Otto T., Krege S., Suhr J., and Rübben H. Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 57 (2001) 55-59
19. Herr H.W., Bochner B.H., Dalbagni G., Donat S.M., Reuter V.E., and Bajorin D.F. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 167 (2002) 1295-1298
20. Kassouf W., Leibovici D., Munsell M.F., Dinney C.P., Grossman H.B., and Kamat A.M. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 176 (2006) 53-57